Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500
Debt
Debt-to-Equity Ratio0.96
Current Ratio2.34
Quick Ratio2.32
Price-To-Earnings
Trailing P/E Ratio71.94
Forward P/E Ratio32.38
P/E Growth1.64
Sales & Book Value
Annual Sales$141.10 million
Price / Sales27.65
Cash Flow$3.7171 per share
Price / Cash49.74
Book Value$18.94 per share
Price / Book9.76
Profitability
EPS (Most Recent Fiscal Year)$2.57
Net Income$12.55 million
Net Margins52.10%
Return on Equity25.95%
Return on Assets12.52%
Miscellaneous
Employees39
Outstanding Shares21,100,000
Market Cap$3.96 billion
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) released its quarterly earnings results on Monday, August, 6th. The biotechnology company reported $2.59 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.34 by $0.25. The biotechnology company earned $90 million during the quarter, compared to the consensus estimate of $82.20 million. Ligand Pharmaceuticals had a return on equity of 25.95% and a net margin of 52.10%. The firm's quarterly revenue was up 221.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 EPS. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals updated its FY18 earnings guidance on Monday, August, 6th. The company provided earnings per share guidance of ~$6.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.21. The company issued revenue guidance of ~$232 million, compared to the consensus revenue estimate of $227.36 million.
What price target have analysts set for LGND?
7 brokerages have issued twelve-month price objectives for Ligand Pharmaceuticals' stock. Their forecasts range from $105.00 to $300.00. On average, they anticipate Ligand Pharmaceuticals' share price to reach $231.4286 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.
What is the consensus analysts' recommendation for Ligand Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and are raising our price target to $239 from $182. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 165 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales and collaborative revenue. Below we show our updated clinical NPV valuation model, which accounts for updates to the ‘Next 12’ assets as well as progress for the later stage assets included." (6/28/2018)
- 2. According to Zacks Investment Research, "Ligand’s earnings and sales beat estimates in the first quarter of 2018. The company’s Captisol Formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, with regard to Ligand’s internal pipeline, there are several candidates in development that could generate future licensing opportunities. Shares of Ligand have outperformed the broader industry in the past year. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to either of these products could have a substantial impact. Moreover, Ligand’s dependence on a single supplier to obtain Captisol is concerning." (6/6/2018)
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS) and Catalent (CTLT).
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, CEO & Exec. Director (Age 48)
- Mr. Matthew W. Foehr, Pres & COO (Age 45)
- Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 43)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 49)
- Mr. Todd Pettingill, Director of Corp. Devel.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include State of New Jersey Common Pension Fund D (0.33%), Woodstock Corp (0.32%), Summit Creek Advisors LLC (0.13%), Aperio Group LLC (0.11%), Texas Permanent School Fund (0.06%) and Bank of Montreal Can (0.05%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
Which institutional investors are selling Ligand Pharmaceuticals stock?
LGND stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Summit Creek Advisors LLC, Campbell Newman Asset Management Inc., Woodstock Corp and Texas Permanent School Fund. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.
Which institutional investors are buying Ligand Pharmaceuticals stock?
LGND stock was acquired by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Empowered Funds LLC, Bfsg LLC, NewSquare Capital LLC, Pennsylvania Trust Co, Strs Ohio, First Hawaiian Bank and Aperio Group LLC. View Insider Buying and Selling for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $184.89.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $3.96 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.
What is Ligand Pharmaceuticals' official website?
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
